Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL), a clinical-stage biopharmaceutical firm focusing on innovative cell therapies for cancer, will engage in two key investor conferences. The first is Cantor’s the Future of Oncology Virtual Symposium on April 3, 2023, featuring a panel discussion at 12:00 pm ET and one-on-one meetings on April 4. The second is the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, with a presentation at 9:30 am ET and additional one-on-one meetings on the same day. Webcasts for these events will be available on the Company’s website, with replays accessible for 90 days.

SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 22, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in two upcoming investor conferences.

Cantor’s the Future of Oncology Virtual Symposium
Panel: April 3^rd at 12:00 pm ET
One-on-one meetings: Tuesday, April 4^th, 2023

22^nd Annual Needham Virtual Healthcare Conference
Presentation: April 19^th at 9:30 am ET
One-on-one meetings: Wednesday, April 19^th, 2023

A webcast of the presentation will be available on the News and Events  section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit ir.gracellbio.com.

About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com and follow @GracellBio on LinkedIn.

FAQ

When will Gracell participate in the Cantor’s Future of Oncology Virtual Symposium?

Gracell will participate in the Cantor’s Future of Oncology Virtual Symposium on April 3, 2023.

What time is Gracell's presentation at the Needham Virtual Healthcare Conference?

Gracell's presentation at the Needham Virtual Healthcare Conference is scheduled for April 19, 2023, at 9:30 am ET.

How can I access the webcasts of Gracell's investor presentations?

Webcasts of Gracell's investor presentations will be available on their website and can be replayed for 90 days after the events.

What is the significance of Gracell's participation in these conferences?

Gracell's participation in these conferences highlights its commitment to advancing innovative cancer therapies and engaging with investors.

What are Gracell's main focuses in biopharmaceuticals?

Gracell focuses on developing affordable and effective cell therapies for cancer, utilizing its FasTCAR and TruUCAR technology platforms.